Review anchor
Mitogen-activated protein kinase kinase kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Mitogen-activated protein kinase kinase kinase 1
CHEMBL3956
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mitogen-activated protein kinase kinase kinase 1 as ChEMBL target CHEMBL3956, mapped to UniProt Q13233. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3956
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13233
Mitogen-activated protein kinase kinase kinase 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Mitogen-activated protein kinase kinase kinase 1 matters
Mitogen-activated protein kinase kinase kinase 1 is reviewed as Mitogen-activated protein kinase kinase kinase 1 (UniProt Q13233); Mitogen-activated protein kinase kinase kinase 1 shows clinical signal disease relevance led by psoriasis. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 554 compounds, and 165 assays, with lead potency reaching pChEMBL 8.1.
Protein context
Mitogen-activated protein kinase kinase kinase 1
Mitogen-activated protein kinase kinase kinase 1 Sequence length is 1512 aa.
Review this target as Mitogen-activated protein kinase kinase kinase 1, mapped to UniProt Q13233. Sequence length is 1512 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13233
Protein
Disease context
psoriasis
Mitogen-activated protein kinase kinase kinase 1 shows clinical signal disease relevance led by psoriasis. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include E-6201.
Start review with psoriasis because it currently carries clinical signal support. Linked drugs include E-6201. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 12 approved drugs, 554 compounds, and 165 assays for this target. The dominant activity type is KD. CHEMBL318804 is the current potency anchor at pChEMBL 8.1.
Use CHEMBL318804 as the tractability anchor when discussing potency (pChEMBL 8.1).
Activity source · ChEMBL 36 via Core Engine
12 approved
pChEMBL 8.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Mitogen-activated protein kinase kinase kinase 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13233, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why psoriasis is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
554
Total Compounds
165
Total Assays
12
Approved Drugs
IC50: 31.0, KD: 325.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL318804
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL2216826
|
7.5 | IC50 | — |
|
|
No preferred name
CHEMBL1097700
|
7.3 | IC50 | — |
|
|
No preferred name
CHEMBL3577124
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL607707
|
7.0 | Kd | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
REGORAFENIB
CHEMBL1946170
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
Source Header